Literature DB >> 32804094

Resilience of Alzheimer's Disease to COVID-19.

Jingwen Li1, Xi Long2, Heqing Huang3, Jine Tang4, Chunli Zhu5, Shaoping Hu6, Jing Wu7, Jinghong Li8, Zhicheng Lin9, Nian Xiong1,5.   

Abstract

BACKGROUND: Facing the novel coronavirus disease 2019 (COVID-19), most vulnerable individuals are seniors, especially those with comorbidities. More attention needs to been paid to the COVID-19 patients with Alzheimer's disease (AD), which is the top age-related neurodegenerative disease.
OBJECTIVE: Since it is unclear whether AD patients are prone to COVID-19 infection and progression to severe stages, we report for the first time a retrospective analysis of the clinical characteristics of AD patients with COVID-19 pneumonia.
METHODS: We conducted a retrospective cohort study of the clinical data of 19 AD patients with COVID-19 pneumonia, compared with 23 non-AD COVID-19 patients admitted at the same time to our hospital. Demographic, clinical, laboratory, radiological, and treatment data were collected and analyzed.
RESULTS: Between AD patients and non-AD patients with COVID-19 pneumonia, the pneumonia severity was not significantly different. AD patients had a higher clustering onset than non-AD patients. The median duration from symptom onset to hospitalization were shorter in AD patients than non-AD patients, indicating the former were sent to the hospital by their family or from nursing home earlier than the later. The median duration from hospitalization to discharge seemed shorter in AD patients than non-AD patients. Dementia patients seemed less likely to report fatigue. It is noticed that more AD patients might have pericardial effusion than the non-AD patients.
CONCLUSION: AD patients with COVID-19 were in milder conditions with a better prognosis than non-AD patients. AD patients who had adequate access to healthcare showed resilience to COVID-19 with shorter hospital stays.

Entities:  

Keywords:  Alzheimer’s disease; COVID-19; clinical characteristics

Mesh:

Year:  2020        PMID: 32804094      PMCID: PMC7592684          DOI: 10.3233/JAD-200649

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  19 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  ApoE genotype accounts for the vast majority of AD risk and AD pathology.

Authors:  Jacob Raber; Yadong Huang; J Wesson Ashford
Journal:  Neurobiol Aging       Date:  2004 May-Jun       Impact factor: 4.673

3.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

4.  Apolipoprotein ɛ4 Allele and Dental Occlusion Deficiency as Risk Factors for Alzheimer's Disease.

Authors:  Aleksandra Popovac; Irena Mladenović; Jelena Krunić; Branka Trifković; Ana Todorović; Jelena Milašin; Nebojša Despotović; Ivica Stančić
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Genetic resilience to Alzheimer's disease in APOE ε4 homozygotes: A systematic review.

Authors:  Aamira J Huq; Peter Fransquet; Simon M Laws; Joanne Ryan; Robert Sebra; Colin L Masters; Ingrid M Winship; Paul A James; Paul Lacaze
Journal:  Alzheimers Dement       Date:  2019-09-07       Impact factor: 21.566

6.  Invisible spread of SARS-CoV-2.

Authors:  Nian Xiong; Tao Wang; Zhicheng Lin
Journal:  Lancet Infect Dis       Date:  2020-04-08       Impact factor: 25.071

7.  ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Charles E Evans; James S Miners; Giulia Piva; Christine L Willis; David M Heard; Emma J Kidd; Mark A Good; Patrick G Kehoe
Journal:  Acta Neuropathol       Date:  2020-01-25       Impact factor: 15.887

8.  Dementia care during COVID-19.

Authors:  Huali Wang; Tao Li; Paola Barbarino; Serge Gauthier; Henry Brodaty; José Luis Molinuevo; Hengge Xie; Yongan Sun; Enyan Yu; Yanqing Tang; Wendy Weidner; Xin Yu
Journal:  Lancet       Date:  2020-03-30       Impact factor: 79.321

9.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  7 in total

1.  Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action.

Authors:  Lin Liu; Shu-Yu Ni; Wei Yan; Qing-Dong Lu; Yi-Miao Zhao; Ying-Ying Xu; Huan Mei; Le Shi; Kai Yuan; Ying Han; Jia-Hui Deng; Yan-Kun Sun; Shi-Qiu Meng; Zheng-Dong Jiang; Na Zeng; Jian-Yu Que; Yong-Bo Zheng; Bei-Ni Yang; Yi-Miao Gong; Arun V Ravindran; Thomas Kosten; Yun Kwok Wing; Xiang-Dong Tang; Jun-Liang Yuan; Ping Wu; Jie Shi; Yan-Ping Bao; Lin Lu
Journal:  EClinicalMedicine       Date:  2021-09-08

2.  COVID-19 Outcomes in Hospitalized Patients With Neurodegenerative Disease: A Retrospective Cohort Study.

Authors:  Roshni Abee Patel; Glenn T Stebbins; Ekta B Kishen; Brandon Barton
Journal:  Neurol Clin Pract       Date:  2022-02

3.  COVID-19 Case Fatality and Alzheimer's Disease.

Authors:  Qiang Zhang; Jordan L Schultz; Georgina M Aldridge; Jacob E Simmering; Youngcho Kim; Amy C Ogilvie; Nandakumar S Narayanan
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.160

4.  COVID-19 related outcomes among individuals with neurodegenerative diseases: a cohort analysis in the UK biobank.

Authors:  Yihan Hu; Huazhen Yang; Can Hou; Wenwen Chen; Hanyue Zhang; Zhiye Ying; Yao Hu; Yajing Sun; Yuanyuan Qu; Maria Feychting; Unnur Valdimarsdottir; Huan Song; Fang Fang
Journal:  BMC Neurol       Date:  2022-01-07       Impact factor: 2.903

Review 5.  Dementia wellbeing and COVID-19: Review and expert consensus on current research and knowledge gaps.

Authors:  Kathy Y Liu; Robert Howard; Sube Banerjee; Adelina Comas-Herrera; Joanne Goddard; Martin Knapp; Gill Livingston; Jill Manthorpe; John T O'Brien; Ross W Paterson; Louise Robinson; Martin Rossor; James B Rowe; David J Sharp; Andrew Sommerlad; Aida Suárez-González; Alistair Burns
Journal:  Int J Geriatr Psychiatry       Date:  2021-05-27       Impact factor: 3.850

Review 6.  A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.

Authors:  Chang-Xing Li; Sobia Noreen; Li-Xue Zhang; Muhammad Saeed; Pei-Feng Wu; Muhammad Ijaz; Dong-Fang Dai; Irsah Maqbool; Asadullah Madni; Faizan Akram; Muhammad Naveed; Jian-Hua Li
Journal:  Biomed Pharmacother       Date:  2021-12-15       Impact factor: 7.419

Review 7.  Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.

Authors:  Saikat Dewanjee; Jayalakshmi Vallamkondu; Rajkumar Singh Kalra; Nagaprasad Puvvada; Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2021-06-24       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.